{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:34:47Z","timestamp":1789756487822,"version":"4.0.1"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T00:00:00Z","timestamp":1324425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s10620-011-2017-z","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T06:45:59Z","timestamp":1324363559000},"page":"610-624","source":"Crossref","is-referenced-by-count":82,"title":["Autoantibody-Negative Autoimmune Hepatitis"],"prefix":"10.1007","volume":"57","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,21]]},"reference":[{"key":"2017_CR1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213.","journal-title":"Hepatology"},{"key":"2017_CR2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/17474124.1.1.129","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007;1:129\u2013143.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2017_CR3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u2013938.","journal-title":"J Hepatol"},{"key":"2017_CR4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2001-13708","volume":"39","author":"S Kanzler","year":"2001","unstructured":"Kanzler S, L\u00f6hr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339\u2013341, 344\u2013338.","journal-title":"Z Gastroenterol"},{"key":"2017_CR5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161\u2013167.","journal-title":"J Hepatol"},{"key":"2017_CR6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","volume":"48","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540\u20131548.","journal-title":"Hepatology"},{"key":"2017_CR7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1053\/j.gastro.2011.02.010","volume":"140","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology. 2011;140:1472\u20131480.","journal-title":"Gastroenterology"},{"key":"2017_CR8","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s10620-011-1769-9","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421\u20133438.","journal-title":"Dig Dis Sci"},{"key":"2017_CR9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1440-1746.1990.tb01624.x","volume":"5","author":"PJ Johnson","year":"1990","unstructured":"Johnson PJ, McFarlane IG, McFarlane BM, Williams R. Auto-immune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibodies. J Gastroenterol Hepatol. 1990;5:244\u2013251.","journal-title":"J Gastroenterol Hepatol"},{"key":"2017_CR10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56:545\u2013554.","journal-title":"Dig Dis Sci"},{"key":"2017_CR11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.510240515","volume":"24","author":"AJ Czaja","year":"1996","unstructured":"Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996;24:1068\u20131073.","journal-title":"Hepatology"},{"key":"2017_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/jaut.2001.0540","volume":"17","author":"EL Can\u00e7ado","year":"2001","unstructured":"Can\u00e7ado EL, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Autoimmun. 2001;17:223\u2013228.","journal-title":"J Autoimmun"},{"key":"2017_CR13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","volume":"51","author":"M Baeres","year":"2002","unstructured":"Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA\/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259\u2013264.","journal-title":"Gut"},{"key":"2017_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","volume":"41","author":"D Vergani","year":"2004","unstructured":"Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41:677\u2013683.","journal-title":"J Hepatol"},{"key":"2017_CR15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1196\/annals.1313.028","volume":"1050","author":"P Chretien-Leprince","year":"2005","unstructured":"Chretien-Leprince P, Ballot E, Andre C, et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann N Y Acad Sci. 2005;1050:266\u2013273.","journal-title":"Ann N Y Acad Sci"},{"key":"2017_CR16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1478-3231.2005.01079.x","volume":"25","author":"AX Torres-Collado","year":"2005","unstructured":"Torres-Collado AX, Czaja AJ, Gelp\u00ed C. Anti-tRNP(ser)sec\/SLA\/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8\u00a0kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int. 2005;25:410\u2013419.","journal-title":"Liver Int"},{"key":"2017_CR17","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/j.1572-0241.2006.00830.x","volume":"101","author":"C Frenzel","year":"2006","unstructured":"Frenzel C, Herkel J, L\u00fcth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol. 2006;101:2731\u20132736.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jcp.2005.027367","volume":"59","author":"A Granito","year":"2006","unstructured":"Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol. 2006;59:280\u2013284.","journal-title":"J Clin Pathol"},{"key":"2017_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10875-006-9045-z","volume":"26","author":"P Gu\u00e9guen","year":"2006","unstructured":"Gu\u00e9guen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol. 2006;26:495\u2013505.","journal-title":"J Clin Immunol"},{"key":"2017_CR20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jcla.20274","volume":"22","author":"V Aubert","year":"2008","unstructured":"Aubert V, Pisler IG, Spertini F. Improved diagnoses of autoimmune hepatitis using an anti-actin ELISA. J Clin Lab Anal. 2008;22:340\u2013345.","journal-title":"J Clin Lab Anal"},{"key":"2017_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cca.2009.06.035","volume":"408","author":"G Hausdorf","year":"2009","unstructured":"Hausdorf G, Roggenbuck D, Feist E, et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA\u2014revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta. 2009;408:19\u201324.","journal-title":"Clin Chim Acta"},{"key":"2017_CR22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.gastro.2010.04.053","volume":"139","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58\u201372.","journal-title":"Gastroenterology"},{"key":"2017_CR23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-2423(05)40004-9","volume":"40","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127\u2013164.","journal-title":"Adv Clin Chem"},{"key":"2017_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0025-6196(12)62106-5","volume":"65","author":"AJ Czaja","year":"1990","unstructured":"Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc. 1990;65:23\u201330.","journal-title":"Mayo Clin Proc"},{"key":"2017_CR25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/0016-5085(93)90656-W","volume":"104","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104:1755\u20131761.","journal-title":"Gastroenterology"},{"key":"2017_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0168-8278(98)80205-5","volume":"28","author":"S Kaymakoglu","year":"1998","unstructured":"Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol. 1998;28:78\u201383.","journal-title":"J Hepatol"},{"key":"2017_CR27","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s10620-006-9665-4","volume":"52","author":"DJ Gassert","year":"2007","unstructured":"Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433\u20132437.","journal-title":"Dig Dis Sci"},{"key":"2017_CR28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2006-927280","volume":"45","author":"A Potthoff","year":"2007","unstructured":"Potthoff A, Deterding K, Trautwein C, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007;45:15\u201319.","journal-title":"Z Gastroenterol"},{"key":"2017_CR29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-0028-1109146","volume":"47","author":"S Heringlake","year":"2009","unstructured":"Heringlake S, Sch\u00fctte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47:417\u2013423.","journal-title":"Z Gastroenterol"},{"key":"2017_CR30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.1840110413","volume":"11","author":"U Treichel","year":"1990","unstructured":"Treichel U, Poralla T, Hess G, Manns M, Meyer zum B\u00fcschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology. 1990;11:606\u2013612.","journal-title":"Hepatology"},{"key":"2017_CR31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.1840160407","volume":"16","author":"N Abuaf","year":"1992","unstructured":"Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892\u2013898.","journal-title":"Hepatology"},{"key":"2017_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","volume":"32","author":"AJ Montano-Loza","year":"2012","unstructured":"Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85\u201392.","journal-title":"Liver Int"},{"key":"2017_CR33","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1440-1746.2008.05365.x","volume":"23","author":"S Seo","year":"2008","unstructured":"Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410\u20131414.","journal-title":"J Gastroenterol Hepatol"},{"key":"2017_CR34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/BF01296447","volume":"31","author":"RP Kenny","year":"1986","unstructured":"Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci. 1986;31:705\u2013711.","journal-title":"Dig Dis Sci"},{"key":"2017_CR35","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/0016-5085(93)90160-E","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105:1522\u20131528.","journal-title":"Gastroenterology"},{"key":"2017_CR36","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1440-1746.2006.04434.x","volume":"21","author":"S Nezu","year":"2006","unstructured":"Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006;21:1448\u20131454.","journal-title":"J Gastroenterol Hepatol"},{"key":"2017_CR37","first-page":"221","volume":"55","author":"S Mishima","year":"2008","unstructured":"Mishima S, Omagari K, Ohba K, et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology. 2008;55:221\u2013227.","journal-title":"Hepatogastroenterology"},{"key":"2017_CR38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/MCG.0b013e3181587d18","volume":"42","author":"AJ Montano-Loza","year":"2008","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047\u20131053.","journal-title":"J Clin Gastroenterol"},{"key":"2017_CR39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","volume":"48","author":"C O\u2019Brien","year":"2008","unstructured":"O\u2019Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48:550\u2013556.","journal-title":"Hepatology"},{"key":"2017_CR40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-008-2254-x","volume":"43","author":"K Fujiwara","year":"2008","unstructured":"Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008;43:951\u2013958.","journal-title":"J Gastroenterol"},{"key":"2017_CR41","first-page":"1233","volume":"52","author":"T Kanda","year":"2005","unstructured":"Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233\u20131235.","journal-title":"Hepatogastroenterology"},{"key":"2017_CR42","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1478-3231.2011.02524.x","volume":"31","author":"K Fujiwara","year":"2011","unstructured":"Fujiwara K, Yasui S, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int. 2011;31:1013\u20131020.","journal-title":"Liver Int"},{"key":"2017_CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1872-034X.2010.00755.x","volume":"41","author":"K Fujiwara","year":"2011","unstructured":"Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res. 2011;41:133\u2013141.","journal-title":"Hepatol Res"},{"key":"2017_CR44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jhep.2007.05.011","volume":"47","author":"W Bernal","year":"2007","unstructured":"Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:664\u2013670.","journal-title":"J Hepatol"},{"key":"2017_CR45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1440-1746.2008.05402.x","volume":"23","author":"A Hiramatsu","year":"2008","unstructured":"Hiramatsu A, Takahashi S, Aikata H, et al. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol. 2008;23:1216\u20131222.","journal-title":"J Gastroenterol Hepatol"},{"key":"2017_CR46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cgh.2008.08.043","volume":"7","author":"V Mehendiratta","year":"2009","unstructured":"Mehendiratta V, Mitroo P, Bombonati A, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2009;7:98\u2013103.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2017_CR47","first-page":"217","volume":"62","author":"Y Miyake","year":"2008","unstructured":"Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med Okayama. 2008;62:217\u2013226.","journal-title":"Acta Med Okayama"},{"key":"2017_CR48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646\u2013652.","journal-title":"J Hepatol"},{"key":"2017_CR49","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","volume":"29","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816\u2013823.","journal-title":"Liver Int"},{"key":"2017_CR50","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1023\/A:1018836004279","volume":"43","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149\u20132155.","journal-title":"Dig Dis Sci"},{"key":"2017_CR51","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824\u20131832.","journal-title":"Gastroenterology"},{"key":"2017_CR52","first-page":"1233","volume":"52","author":"T Kanda","year":"2005","unstructured":"Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233\u20131235.","journal-title":"Hepatogastroenterology"},{"key":"2017_CR53","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02093820","volume":"41","author":"AJ Czaja","year":"1996","unstructured":"Czaja AJ, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996;41:305\u2013314.","journal-title":"Dig Dis Sci"},{"key":"2017_CR54","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1023\/A:1018875401612","volume":"43","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ. Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. Dig Dis Sci. 1998;43:1725\u20131731.","journal-title":"Dig Dis Sci"},{"key":"2017_CR55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4065\/74.9.917","volume":"74","author":"DJ Brandhagen","year":"1999","unstructured":"Brandhagen DJ, Fairbanks VF, Batts KP, Thibodeau SN. Update on hereditary hemochromatosis and the HFE gene. Mayo Clin Proc. 1999;74:917\u2013921.","journal-title":"Mayo Clin Proc"},{"key":"2017_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(97)11222-3","volume":"352","author":"U Volta","year":"1998","unstructured":"Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998;352:26\u201329.","journal-title":"Lancet"},{"key":"2017_CR57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/gast.2002.32416","volume":"122","author":"K Kaukinen","year":"2002","unstructured":"Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology. 2002;122:881\u2013888.","journal-title":"Gastroenterology"},{"key":"2017_CR58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1542-3565(03)00313-6","volume":"2","author":"A Abdo","year":"2004","unstructured":"Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol. 2004;2:107\u2013112.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2017_CR59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1386-6346(02)00274-7","volume":"25","author":"N Okano","year":"2003","unstructured":"Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263\u2013270.","journal-title":"Hepatol Res"},{"key":"2017_CR60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1542-3565(04)00246-0","volume":"2","author":"WR Kessler","year":"2004","unstructured":"Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625\u2013631.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2017_CR61","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2007.05.031","volume":"5","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5:898\u2013907.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2017_CR62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000282084","volume":"28","author":"EE Powell","year":"2010","unstructured":"Powell EE, Jonsson JR, Clouston AD. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis. 2010;28:186\u2013191.","journal-title":"Dig Dis"},{"key":"2017_CR63","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1665-2681(19)31748-X","volume":"8","author":"SH Caldwell","year":"2009","unstructured":"Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8:346\u2013352.","journal-title":"Ann Hepatol"},{"key":"2017_CR64","first-page":"99","volume":"8","author":"HO Akbar","year":"2002","unstructured":"Akbar HO. Cryptogenic or autoimmune hepatitis. Saudi J Gastroenterol. 2002;8:99\u2013101.","journal-title":"Saudi J Gastroenterol"},{"key":"2017_CR65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u2013176.","journal-title":"Hepatology"},{"key":"2017_CR66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/egh.09.15","volume":"3","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269\u2013291.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2017_CR67","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","volume":"63","author":"RD Soloway","year":"1972","unstructured":"Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820\u2013833.","journal-title":"Gastroenterology"},{"key":"2017_CR68","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","volume":"16","author":"WH Summerskill","year":"1975","unstructured":"Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876\u2013883.","journal-title":"Gut"},{"key":"2017_CR69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1990.tb03606.x","volume":"30","author":"GL Chan","year":"1990","unstructured":"Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30:358\u2013363.","journal-title":"J Clin Pharmacol"},{"key":"2017_CR70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC. Immunosuppressive drugs: the first 50\u00a0years and a glance forward. Immunopharmacology. 2000;47:63\u201383.","journal-title":"Immunopharmacology"},{"key":"2017_CR71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","volume":"95","author":"AJ Czaja","year":"1988","unstructured":"Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448\u2013453.","journal-title":"Gastroenterology"},{"key":"2017_CR72","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","volume":"102","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005\u20131012.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR73","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198\u20131206.","journal-title":"Gastroenterology"},{"key":"2017_CR74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840150208","volume":"15","author":"L Sanchez-Urdazpal","year":"1992","unstructured":"Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215\u2013221.","journal-title":"Hepatology"},{"key":"2017_CR75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0168-8278(99)80017-8","volume":"30","author":"V Ratziu","year":"1999","unstructured":"Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30:131\u2013141.","journal-title":"J Hepatol"},{"key":"2017_CR76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1432-2277.2002.tb00095.x","volume":"15","author":"P Cattan","year":"2002","unstructured":"Cattan P, Berney T, Conti F, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int. 2002;15:34\u201338.","journal-title":"Transpl Int"},{"key":"2017_CR77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2002-30101","volume":"22","author":"D Larrey","year":"2002","unstructured":"Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145\u2013155.","journal-title":"Semin Liver Dis"},{"key":"2017_CR78","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0041-1345(03)00591-8","volume":"35","author":"O N\u00fa\u00f1ez-Mart\u00ednez","year":"2003","unstructured":"N\u00fa\u00f1ez-Mart\u00ednez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transplant Proc. 2003;35:1857\u20131858.","journal-title":"Transplant Proc"},{"key":"2017_CR79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0012.2004.00117.x","volume":"18","author":"A Vogel","year":"2004","unstructured":"Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18:62\u201369.","journal-title":"Clin Transplant"},{"key":"2017_CR80","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.transproceed.2007.02.030","volume":"39","author":"H Khalaf","year":"2007","unstructured":"Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc. 2007;39:1166\u20131170.","journal-title":"Transplant Proc"},{"key":"2017_CR81","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/lt.22018","volume":"16","author":"C Schramm","year":"2010","unstructured":"Schramm C, Bubenheim M, Adam R, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010;16:461\u2013469.","journal-title":"Liver Transpl"},{"key":"2017_CR82","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/lt.21525","volume":"14","author":"J Campsen","year":"2008","unstructured":"Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008;14:1281\u20131286.","journal-title":"Liver Transpl"},{"key":"2017_CR83","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2002-35707","volume":"22","author":"J Neuberger","year":"2002","unstructured":"Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis. 2002;22:379\u2013386.","journal-title":"Semin Liver Dis"},{"key":"2017_CR84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0029-1233531","volume":"29","author":"D Tripathi","year":"2009","unstructured":"Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29:286\u2013296.","journal-title":"Semin Liver Dis"},{"key":"2017_CR85","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1399-0012.2004.00323.x","volume":"19","author":"JC Duclos-Vall\u00e9e","year":"2005","unstructured":"Duclos-Vall\u00e9e JC, Yilmaz F, Johanet C, et al. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transplant. 2005;19:591\u2013599.","journal-title":"Clin Transplant"},{"key":"2017_CR86","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/lt.500030402","volume":"3","author":"MR Charlton","year":"1997","unstructured":"Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RA, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997;3:359\u2013364.","journal-title":"Liver Transpl Surg"},{"key":"2017_CR87","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJM200105243442103","volume":"344","author":"NO Ku","year":"2001","unstructured":"Ku NO, Gish R, Wright TL, Omary MB. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med. 2001;344:1580\u20131587.","journal-title":"N Engl J Med"},{"key":"2017_CR88","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/lt.21108","volume":"13","author":"WK Syn","year":"2007","unstructured":"Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl. 2007;13:984\u2013989.","journal-title":"Liver Transpl"},{"key":"2017_CR89","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.transproceed.2003.10.059","volume":"35","author":"A Sanjeevi","year":"2003","unstructured":"Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnarayan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc. 2003;35:2977\u20132980.","journal-title":"Transplant Proc"},{"key":"2017_CR90","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/lt.22004","volume":"16","author":"K Yalamanchili","year":"2010","unstructured":"Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transplant. 2010;16:431\u2013439.","journal-title":"Liver Transplant"},{"key":"2017_CR91","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1053\/jlts.2003.50165","volume":"9","author":"MA Heneghan","year":"2003","unstructured":"Heneghan MA, Zolfino T, Muiesan P, et al. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2003;9:921\u2013928.","journal-title":"Liver Transpl"},{"key":"2017_CR92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0753-3322(99)80096-1","volume":"53","author":"IG McFarlane","year":"1999","unstructured":"McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother. 1999;53:255\u2013263.","journal-title":"Biomed Pharmacother"},{"key":"2017_CR93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474124.1.1.113","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113\u2013128.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2017_CR94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.trsl.2006.11.010","volume":"149","author":"P Lapierre","year":"2007","unstructured":"Lapierre P, B\u00e9land K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res. 2007;149:107\u2013113.","journal-title":"Transl Res"},{"key":"2017_CR95","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3748\/wjg.14.3306","volume":"14","author":"D Vergani","year":"2008","unstructured":"Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008;14:3306\u20133312.","journal-title":"World J Gastroenterol"},{"key":"2017_CR96","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s10620-010-1268-4","volume":"55","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144\u20132161.","journal-title":"Dig Dis Sci"},{"key":"2017_CR97","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","volume":"30","author":"AJ Czaja","year":"1999","unstructured":"Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394\u2013401.","journal-title":"J Hepatol"},{"key":"2017_CR98","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gut.42.5.721","volume":"42","author":"L Muratori","year":"1998","unstructured":"Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver\/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42:721\u2013726.","journal-title":"Gut"},{"key":"2017_CR99","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0953-6205(02)00089-4","volume":"13","author":"GN Dalekos","year":"2002","unstructured":"Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med. 2002;13:293\u2013303.","journal-title":"Eur J Intern Med"},{"key":"2017_CR100","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","volume":"97","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen\/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413\u2013419.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR101","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0168-8278(99)80342-0","volume":"31","author":"S Kanzler","year":"1999","unstructured":"Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999;31:635\u2013640.","journal-title":"J Hepatol"},{"key":"2017_CR102","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0891693021000054101","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen\/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475\u2013483.","journal-title":"Autoimmunity"},{"key":"2017_CR103","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/BF02088738","volume":"41","author":"AJ Czaja","year":"1996","unstructured":"Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci. 1996;41:1733\u20131740.","journal-title":"Dig Dis Sci"},{"key":"2017_CR104","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0168-8278(86)80026-5","volume":"3","author":"BM McFarlane","year":"1986","unstructured":"McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 1986;3:196\u2013205.","journal-title":"J Hepatol"},{"key":"2017_CR105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF02919748","volume":"10","author":"KH Meyer zum B\u00fcschenfelde","year":"1991","unstructured":"Meyer zum B\u00fcschenfelde KH, Treichel U, L\u00f6hr H, Fleischer B, Poralla T. Human asialoglycoprotein receptor as an autoantigen in chronic hepatitis. Immunol Res. 1991;10:497\u2013502.","journal-title":"Immunol Res"},{"key":"2017_CR106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0168-8278(05)80176-X","volume":"19","author":"U Treichel","year":"1993","unstructured":"Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum B\u00fcschenfelde KH, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol. 1993;19:55\u201363.","journal-title":"J Hepatol"},{"key":"2017_CR107","first-page":"15","volume":"35","author":"D Dejica","year":"1997","unstructured":"Dejica D, Treichel U, P\u00e1r A, Chira O, Meyer zum B\u00fcschenfelde KH. Anti asialoglycoprotein receptor antibodies and soluble interleukin-2 receptor levels as marker for inflammation in autoimmune hepatitis. Z Gastroenterol. 1997;35:15\u201321.","journal-title":"Z Gastroenterol"},{"key":"2017_CR108","first-page":"99","volume":"56","author":"M Yoshioka","year":"2002","unstructured":"Yoshioka M, Mizuno M, Morisue Y, et al. Anti-asialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases. Acta Med Okayama. 2002;56:99\u2013105.","journal-title":"Acta Med Okayama"},{"key":"2017_CR109","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.20172","volume":"39","author":"P Hilgard","year":"2004","unstructured":"Hilgard P, Schreiter T, Stockert RJ, Gerken G, Treichel U. Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis. Hepatology. 2004;39:1398\u20131407.","journal-title":"Hepatology"},{"key":"2017_CR110","first-page":"7","volume":"45","author":"P Husa","year":"2001","unstructured":"Husa P, Chalupa P, Stroblov\u00e1 H, Husov\u00e1 L, Slesinger P, Zaj\u00edc J. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients. Acta Virol. 2001;45:7\u201311.","journal-title":"Acta Virol"},{"key":"2017_CR111","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1572-0241.2001.03630.x","volume":"96","author":"M Sasaki","year":"2001","unstructured":"Sasaki M, Yamauchi K, Tokushige K, et al. Clinical significance of autoantibody to hepatocyte membrane antigen in type 1 autoimmune hepatitis. Am J Gastroenterol. 2001;96:846\u2013851.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR112","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(84)91167-X","volume":"2","author":"IG McFarlane","year":"1984","unstructured":"McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet. 1984;2:954\u2013956.","journal-title":"Lancet"},{"key":"2017_CR113","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2249.1998.00673.x","volume":"113","author":"O Hajoui","year":"1998","unstructured":"Hajoui O, Martin S, Alvarez F. Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies. Clin Exp Immunol. 1998;113:339\u2013345.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2005.01.007","volume":"301","author":"T Schreiter","year":"2005","unstructured":"Schreiter T, Liu C, Gerken G, Treichel U. Detection of circulating autoantibodies directed against the asialoglycoprotein receptor using recombinant receptor subunit H1. J Immunol Methods. 2005;301:1\u201310.","journal-title":"J Immunol Methods"},{"key":"2017_CR115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/hep.1840170310","volume":"17","author":"AH Mulder","year":"1993","unstructured":"Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17:411\u2013417.","journal-title":"Hepatology"},{"key":"2017_CR116","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0016-5085(95)90215-5","volume":"108","author":"SR Targan","year":"1995","unstructured":"Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995;108:1159\u20131166.","journal-title":"Gastroenterology"},{"key":"2017_CR117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0168-8278(96)80144-9","volume":"24","author":"D Bansi","year":"1996","unstructured":"Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 1996;24:581\u2013586.","journal-title":"J Hepatol"},{"key":"2017_CR118","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.510250510","volume":"25","author":"D Zauli","year":"1997","unstructured":"Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997;25:1105\u20131107.","journal-title":"Hepatology"},{"key":"2017_CR119","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004836-200310000-00011","volume":"37","author":"AJ Czaja","year":"2003","unstructured":"Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003;37:315\u2013329.","journal-title":"J Clin Gastroenterol"},{"key":"2017_CR120","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1478-3231.2009.01989.x","volume":"29","author":"V Riva De","year":"2009","unstructured":"De Riva V, Celadin M, Pittoni M, Plebani M, Angeli P. What is behind the presence of anti-neutrophil cytoplasmatic antibodies in chronic liver disease? Liver Int. 2009;29:865\u2013870.","journal-title":"Liver Int"},{"key":"2017_CR121","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/gast.2000.9366","volume":"119","author":"B Terjung","year":"2000","unstructured":"Terjung B, Spengler U, Sauerbruch T, Worman HJ. \u201cAtypical p-ANCA\u201d in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119:310\u2013322.","journal-title":"Gastroenterology"},{"key":"2017_CR122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-008-8088-8","volume":"36","author":"B Terjung","year":"2009","unstructured":"Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a \u201cleaky gut\u201d? Clin Rev Allergy Immunol. 2009;36:40\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2017_CR123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1478-3231.2009.02107.x","volume":"30","author":"JU Sir","year":"2010","unstructured":"Sir JU, Kim TY. Is ANCA really related to chronic liver disease? Liver Int. 2010;30:157\u2013158; author reply 158\u2013159.","journal-title":"Liver Int"},{"key":"2017_CR124","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(05)80508-2","volume":"20","author":"GN Dalekos","year":"1994","unstructured":"Dalekos GN, Tsianos EV. Anti-neutrophil antibodies in chronic viral hepatitis. J Hepatol. 1994;20:561.","journal-title":"J Hepatol"},{"key":"2017_CR125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0016-5085(99)70186-1","volume":"116","author":"P Lapierre","year":"1999","unstructured":"Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643\u2013649.","journal-title":"Gastroenterology"},{"key":"2017_CR126","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/jhep.2001.27179","volume":"34","author":"L Muratori","year":"2001","unstructured":"Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology. 2001;34:494\u2013501.","journal-title":"Hepatology"},{"key":"2017_CR127","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/hep.1840080632","volume":"8","author":"E Martini","year":"1988","unstructured":"Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988;8:1662\u20131666.","journal-title":"Hepatology"},{"key":"2017_CR128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.36.5.749","volume":"36","author":"M Lenzi","year":"1995","unstructured":"Lenzi M, Manotti P, Muratori L, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut. 1995;36:749\u2013754.","journal-title":"Gut"},{"key":"2017_CR129","first-page":"58","volume":"21","author":"S Han","year":"1995","unstructured":"Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology. 1995;21:58\u201362.","journal-title":"Hepatology"},{"key":"2017_CR130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/08916930410001702469","volume":"37","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity. 2004;37:195\u2013201.","journal-title":"Autoimmunity"},{"key":"2017_CR131","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(94)91966-6","volume":"344","author":"T Philipp","year":"1994","unstructured":"Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994;344:578\u2013581.","journal-title":"Lancet"},{"key":"2017_CR132","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0016-5085(95)90074-8","volume":"108","author":"M Durazzo","year":"1995","unstructured":"Durazzo M, Philipp T, Van Pelt FN, et al. Heterogeneity of liver\u2013kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology. 1995;108:455\u2013462.","journal-title":"Gastroenterology"},{"key":"2017_CR133","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0016-5085(96)70020-3","volume":"111","author":"CP Strassburg","year":"1996","unstructured":"Strassburg CP, Obermayer-Straub P, Alex B, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology. 1996;111:1576\u20131586.","journal-title":"Gastroenterology"},{"key":"2017_CR134","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1572-0241.2001.03383.x","volume":"96","author":"A Csepregi","year":"2001","unstructured":"Csepregi A, Nemes\u00e1nszky E, Luettig B, Obermayer-Straub P, Manns MP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol. 2001;96:910\u2013911.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00351174","volume":"23","author":"P Obermayer-Straub","year":"1996","unstructured":"Obermayer-Straub P, Manns MP. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23:235\u2013242.","journal-title":"Mol Biol Rep"},{"key":"2017_CR136","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510260438","volume":"26","author":"MP Manns","year":"1997","unstructured":"Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate\u2013glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26:1054\u20131066.","journal-title":"Hepatology"},{"key":"2017_CR137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(90)90291-3","volume":"130","author":"M Fusconi","year":"1990","unstructured":"Fusconi M, Cassani F, Zauli D, et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods. 1990;130:1\u20138.","journal-title":"J Immunol Methods"},{"key":"2017_CR138","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcla.20167","volume":"21","author":"TD Jaskowski","year":"2007","unstructured":"Jaskowski TD, Konnick EQ, Ashwood ER, Litwin CM, Hill HR. Prevalence of IgG autoantibody against F-actin in patients suspected of having autoimmune or acute viral hepatitis. J Clin Lab Anal. 2007;21:249\u2013253.","journal-title":"J Clin Lab Anal"},{"key":"2017_CR139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2008.07.011","volume":"338","author":"R Martinez-Neira","year":"2008","unstructured":"Martinez-Neira R, dos Remedios CG, Mackay IR. An actin-myosin functional assay for analysis of smooth muscle (anti-microfilament) autoantibodies in human plasma. J Immunol Methods. 2008;338:63\u201366.","journal-title":"J Immunol Methods"},{"key":"2017_CR140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.autrev.2009.02.023","volume":"8","author":"A Soares","year":"2009","unstructured":"Soares A, Cunha R, Rodrigues F, Ribeiro H. Smooth muscle autoantibodies with F-actin specificity. Autoimmun Rev. 2009;8:713\u2013716.","journal-title":"Autoimmun Rev"},{"key":"2017_CR141","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/08916930701619896","volume":"41","author":"D Villalta","year":"2008","unstructured":"Villalta D, Bizzaro N, Da Re M, Tozzoli R, Komorowski L, Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity. 2008;41:105\u2013110.","journal-title":"Autoimmunity"},{"key":"2017_CR142","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0896-8411(03)00036-2","volume":"20","author":"A Zamanou","year":"2003","unstructured":"Zamanou A, Samiotaki M, Panayotou G, Margaritis L, Lymberi P. Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun. 2003;20:333\u2013344.","journal-title":"J Autoimmun"},{"key":"2017_CR143","first-page":"266","volume":"24","author":"K Lidman","year":"1976","unstructured":"Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol. 1976;24:266\u2013272.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR144","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.autrev.2010.12.009","volume":"10","author":"KG Oikonomou","year":"2011","unstructured":"Oikonomou KG, Zachou K, Dalekos GN. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev. 2011;10:389\u2013396.","journal-title":"Autoimmun Rev"},{"key":"2017_CR145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12016-007-8050-1","volume":"34","author":"Y Renaudineau","year":"2008","unstructured":"Renaudineau Y, Dalekos GN, Gu\u00e9guen P, Zachou K, Youinou P. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol. 2008;34:321\u2013325.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2017_CR146","first-page":"619","volume":"99","author":"U Volta","year":"2008","unstructured":"Volta U. Liver dysfunction in celiac disease. Minerva Med. 2008;99:619\u2013629.","journal-title":"Minerva Med"},{"key":"2017_CR147","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(57)91895-0","volume":"273","author":"IR Mackay","year":"1957","unstructured":"Mackay IR, Larkin L, Burnet FM. Failure of autoimmune antibody to react with antigen prepared from the individual\u2019s own tissues. Lancet. 1957;273:122\u2013123.","journal-title":"Lancet"},{"key":"2017_CR148","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(59)91136-5","volume":"1","author":"IR Mackay","year":"1959","unstructured":"Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959;1:65\u201369.","journal-title":"Lancet"},{"key":"2017_CR149","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJM197603112941103","volume":"294","author":"U Hopf","year":"1976","unstructured":"Hopf U, Meyer zum B\u00fcschenfelde KH, Arnold W. Detection of a liver\u2013membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med. 1976;294:578\u2013582.","journal-title":"N Engl J Med"},{"key":"2017_CR150","first-page":"213","volume":"54","author":"IH Frazer","year":"1983","unstructured":"Frazer IH, Kronborg IJ, Mackay IR. Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH. Clin Exper Immunol. 1983;54:213\u2013218.","journal-title":"Clin Exper Immunol"},{"key":"2017_CR151","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.510260306","volume":"26","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567\u2013572.","journal-title":"Hepatology"},{"key":"2017_CR152","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0168-8278(95)80308-4","volume":"23","author":"AJ Czaja","year":"1995","unstructured":"Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol. 1995;23:32\u201338.","journal-title":"J Hepatol"},{"key":"2017_CR153","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1440-1746.1998.tb00673.x","volume":"13","author":"M Chen","year":"1998","unstructured":"Chen M, Shirai M, Czaja AJ, et al. Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:483\u2013489.","journal-title":"J Gastroenterol Hepatol"},{"key":"2017_CR154","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1046\/j.1440-1746.2000.02325.x","volume":"15","author":"L Li","year":"2000","unstructured":"Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol. 2000;15:1176\u20131182.","journal-title":"J Gastroenterol Hepatol"},{"key":"2017_CR155","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1023\/A:1024748714580","volume":"48","author":"AJ Czaja","year":"2003","unstructured":"Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci. 2003;48:1658\u20131664.","journal-title":"Dig Dis Sci"},{"key":"2017_CR156","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0016-5085(94)90078-7","volume":"107","author":"AJ Czaja","year":"1994","unstructured":"Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 1994;107:200\u2013207.","journal-title":"Gastroenterology"},{"key":"2017_CR157","first-page":"621","volume":"38","author":"BH Toh","year":"1979","unstructured":"Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol. 1979;38:621\u2013628.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR158","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2036.2005.02686.x","volume":"22","author":"M Fusconi","year":"2005","unstructured":"Fusconi M, Vannini A, Dall\u2019Aglio AC, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2005;22:951\u2013955.","journal-title":"Aliment Pharmacol Ther"},{"key":"2017_CR159","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/08916930600783348","volume":"39","author":"A Montano-Loza","year":"2006","unstructured":"Montano-Loza A, Czaja AJ, Carpenter HA, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity. 2006;39:341\u2013348.","journal-title":"Autoimmunity"},{"key":"2017_CR160","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1572-0241.1998.444_n.x","volume":"93","author":"M Ohana","year":"1998","unstructured":"Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol. 1998;93:1334\u20131339.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR161","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2249.2003.02166.x","volume":"132","author":"P Muratori","year":"2003","unstructured":"Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473\u2013476.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR162","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/B:DDAS.0000026306.36511.c8","volume":"49","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig Dis Sci. 2004;49:611\u2013618.","journal-title":"Dig Dis Sci"},{"key":"2017_CR163","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1023\/A:1018880429469","volume":"43","author":"S Parveen","year":"1998","unstructured":"Parveen S, Morshed SA, Arima K, et al. Antibodies to Ro\/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci. 1998;43:1322\u20131331.","journal-title":"Dig Dis Sci"},{"key":"2017_CR164","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.4049\/jimmunol.169.9.4889","volume":"169","author":"I Djilali-Saiah","year":"2002","unstructured":"Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol. 2002;169:4889\u20134896.","journal-title":"J Immunol"},{"key":"2017_CR165","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.20109","volume":"39","author":"P Lapierre","year":"2004","unstructured":"Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology. 2004;39:1066\u20131074.","journal-title":"Hepatology"},{"key":"2017_CR166","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2005.11.001","volume":"26","author":"P Lapierre","year":"2006","unstructured":"Lapierre P, B\u00e9land K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun. 2006;26:82\u201389.","journal-title":"J Autoimmun"},{"key":"2017_CR167","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20071859","volume":"205","author":"M Holdener","year":"2008","unstructured":"Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409\u20131422.","journal-title":"J Exp Med"},{"key":"2017_CR168","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/egh.10.42","volume":"4","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2010;4:429\u2013443.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2017_CR169","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1572-0241.2001.03707.x","volume":"96","author":"AJ Czaja","year":"2001","unstructured":"Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224\u20131231.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR170","first-page":"43","volume":"53","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2007;53:43\u201378.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2017_CR171","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2009.08.010","volume":"34","author":"MS Longhi","year":"2010","unstructured":"Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34:7\u201314.","journal-title":"J Autoimmun"},{"key":"2017_CR172","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","volume":"41","author":"MS Longhi","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31\u201337.","journal-title":"J Hepatol"},{"key":"2017_CR173","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","volume":"25","author":"MS Longhi","year":"2005","unstructured":"Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63\u201371.","journal-title":"J Autoimmun"},{"key":"2017_CR174","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","volume":"176","author":"MS Longhi","year":"2006","unstructured":"Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484\u20134491.","journal-title":"J Immunol"},{"key":"2017_CR175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","volume":"47","author":"MS Longhi","year":"2008","unstructured":"Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581\u2013591.","journal-title":"Hepatology"},{"key":"2017_CR176","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0016-5085(92)91122-K","volume":"103","author":"H Tilg","year":"1992","unstructured":"Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264\u2013274.","journal-title":"Gastroenterology"},{"key":"2017_CR177","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0091-6749(93)90068-Q","volume":"92","author":"A al-Wabel","year":"1993","unstructured":"al-Wabel A, al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol. 1993;92:902\u2013908.","journal-title":"J Allergy Clin Immunol"},{"key":"2017_CR178","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2249.1993.tb05996.x","volume":"94","author":"JF Schlaak","year":"1993","unstructured":"Schlaak JF, L\u00f6hr H, Gallati H, Meyer zum B\u00fcschenfelde KH, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol. 1993;94:168\u2013173.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR179","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00005176-199501000-00005","volume":"20","author":"G Maggiore","year":"1995","unstructured":"Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995;20:23\u201327.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2017_CR180","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.510300412","volume":"30","author":"S Cookson","year":"1999","unstructured":"Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851\u2013856.","journal-title":"Hepatology"},{"key":"2017_CR181","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","volume":"117","author":"AJ Czaja","year":"1999","unstructured":"Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645\u2013652.","journal-title":"Gastroenterology"},{"key":"2017_CR182","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1023\/A:1005506031717","volume":"45","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45:1028\u20131035.","journal-title":"Dig Dis Sci"},{"key":"2017_CR183","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2174\/092986707781696591","volume":"14","author":"W Chen","year":"2007","unstructured":"Chen W, Perruche S, Li J. CD4+CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245\u20132249.","journal-title":"Curr Med Chem"},{"key":"2017_CR184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2006-927397","volume":"45","author":"G Tiegs","year":"2007","unstructured":"Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z Gastroenterol. 2007;45:63\u201370.","journal-title":"Z Gastroenterol"},{"key":"2017_CR185","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2249.1991.tb08164.x","volume":"84","author":"H L\u00f6hr","year":"1991","unstructured":"L\u00f6hr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297\u2013302.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR186","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2249.1992.tb03037.x","volume":"88","author":"H L\u00f6hr","year":"1992","unstructured":"L\u00f6hr H, Treichel U, Poralla T, Manns M, Meyer zum B\u00fcschenfelde KH. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol. 1992;88:45\u201349.","journal-title":"Clin Exp Immunol"},{"key":"2017_CR187","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.12.13.1255","volume":"12","author":"MB Oldstone","year":"1998","unstructured":"Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J. 1998;12:1255\u20131265.","journal-title":"FASEB J"},{"key":"2017_CR188","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1056\/NEJM199912303412707","volume":"341","author":"LJ Albert","year":"1999","unstructured":"Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med. 1999;341:2068\u20132074.","journal-title":"N Engl J Med"},{"key":"2017_CR189","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1034\/j.1600-0676.2001.021004225.x","volume":"21","author":"DP Bogdanos","year":"2001","unstructured":"Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225\u2013232.","journal-title":"Liver"},{"key":"2017_CR190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1089-3261(02)00018-1","volume":"6","author":"D Vergani","year":"2002","unstructured":"Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727\u2013737.","journal-title":"Clin Liver Dis"},{"key":"2017_CR191","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/1744666X.2.1.33","volume":"2","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33\u201348.","journal-title":"Expert Rev Clin Immunol"},{"key":"2017_CR192","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cgh.2007.12.048","volume":"6","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2017_CR193","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","volume":"35","author":"Y Ma","year":"2002","unstructured":"Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658\u2013664.","journal-title":"Hepatology"},{"key":"2017_CR194","first-page":"2197","volume":"92","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol. 1997;92:2197\u20132200.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR195","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1572-0241.1999.01229.x","volume":"94","author":"PL Bittencourt","year":"1999","unstructured":"Bittencourt PL, Goldberg AC, Can\u00e7ado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906\u20131913.","journal-title":"Am J Gastroenterol"},{"key":"2017_CR196","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jhep.2006.07.034","volume":"45","author":"I Djilali-Saiah","year":"2006","unstructured":"Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol. 2006;45:844\u2013850.","journal-title":"J Hepatol"},{"key":"2017_CR197","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10620-006-9495-4","volume":"52","author":"P Muratori","year":"2007","unstructured":"Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver\/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007;52:179\u2013184.","journal-title":"Dig Dis Sci"},{"key":"2017_CR198","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/lt.21088","volume":"13","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953\u2013955.","journal-title":"Liver Transpl"},{"key":"2017_CR199","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958\u2013976.","journal-title":"Dig Dis Sci"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-2017-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-011-2017-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-2017-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:56:06Z","timestamp":1742086566000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-011-2017-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,21]]},"references-count":199,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["2017"],"URL":"https:\/\/doi.org\/10.1007\/s10620-011-2017-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,21]]}}}